4-fluoro-2-methylnaphthalene-1-carbaldehyde | 925442-68-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-fluoro-2-methylnaphthalene-1-carbaldehyde
• 英文别名: 4-fluoro-2-methyl-1-naphthaldehyde
• CAS: 925442-68-8
• 化学式: C₁₂H₉FO
• 分子量: 188.201
• InChiKey: OJKJMRBCQUDDHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-fluoro-2-methylnaphthalene-1-carbaldehyde 、 (9aS)-8-acetyl-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide 在 三乙基硅烷 、 三氟乙酸 作用下， 以 乙腈 为溶剂， 以79%的产率得到(9aS)-8-acetyl-N-[(4-fluoro-2-methylnaphthalen-1-yl)methyl]-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide
  参考文献：
  名称：

  Synthesis and biological evaluation of novel (−)-cercosporamide derivatives as potent selective PPARγ modulators

  摘要：

  Selective peroxisome proliferator-activated receptor gamma (PPAR gamma) modulators are expected to be a novel class of drugs improving plasma glucose levels without PPAR gamma-related adverse effects. As a continuation of our studies for (-)-Cercosporamide derivatives as selective PPAR gamma modulators, we synthesized substituted naphthalene type compounds and identified the most potent compound 15 (EC50 = 0.94 nM, E-max), = 38%). Compound 15 selectively activated PPAR gamma transcription and did not activate PPAR alpha and PPAR delta. The potassium salt of compound 15 showed a high solubility and a good oral bioavailability (58%). Oral administration of the potassium salt remarkably improved the plasma glucose levels of female Zucker diabetic fatty rats at 1 mg/kg. Moreover, it did not cause a plasma volume increase or a cardiac enlargement in Wistar-Imamichi rats, even at 100 mg/kg. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.05.040
• 作为产物：
  描述：

  4-氟-1-萘醛 、 碘甲烷 在 N,N,N'-三甲基乙二胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 26.0h， 以17%的产率得到4-fluoro-2-methylnaphthalene-1-carbaldehyde
  参考文献：
  名称：

  Synthesis and biological evaluation of novel (−)-cercosporamide derivatives as potent selective PPARγ modulators

  摘要：

  Selective peroxisome proliferator-activated receptor gamma (PPAR gamma) modulators are expected to be a novel class of drugs improving plasma glucose levels without PPAR gamma-related adverse effects. As a continuation of our studies for (-)-Cercosporamide derivatives as selective PPAR gamma modulators, we synthesized substituted naphthalene type compounds and identified the most potent compound 15 (EC50 = 0.94 nM, E-max), = 38%). Compound 15 selectively activated PPAR gamma transcription and did not activate PPAR alpha and PPAR delta. The potassium salt of compound 15 showed a high solubility and a good oral bioavailability (58%). Oral administration of the potassium salt remarkably improved the plasma glucose levels of female Zucker diabetic fatty rats at 1 mg/kg. Moreover, it did not cause a plasma volume increase or a cardiac enlargement in Wistar-Imamichi rats, even at 100 mg/kg. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.05.040

文献信息

• Overcoming <i>peri</i>- and <i>ortho</i>-selectivity in C–H methylation of 1-naphthaldehydes by a tunable transient ligand strategy
  作者：Yujian Mao、Jing Jiang、Dandan Yuan、Xiuzhen Chen、Yanan Wang、Lihong Hu、Yinan Zhang

  DOI：10.1039/d1sc05899a

  日期：——

  Aiming to introduce this smallest alkyl handle, a highly regioselective peri- and ortho-C–H methylation of 1-naphthaldehyde by using a transient ligand strategy has been developed. A series of methyl-substituted naphthalene frameworks have been prepared in moderate to excellent yields. Mechanistic studies demonstrate that peri-methylation is controlled by the higher electronic density of the peri-position

  甲基广泛存在于生物活性分子中，位点特异性甲基化已成为其结构功能化的重要策略。为了引入这种最小的烷基手柄，我们开发了一种通过使用瞬时配体策略对 1-萘醛进行高度区域选择性的邻位和邻位-C–H 甲基化的方法。一系列甲基取代的萘骨架已以中等至优异的产率制备。机理研究表明，邻甲基化是由1-萘醛邻位较高的电子密度以及中间5,6-稠合双环钯环的形成控制的，而实验研究和理论计算推断，5元环1-萘醛邻位的铱环通过周围环和邻环之间的相互转化导致能量上有利的邻甲基化。重要的是，为了证明该方法的合成效用，我们证明该策略可以作为合成多取代萘基生物活性分子和天然产物的平台。
• Novel Cercosporamide Derivative
  申请人：Furukawa Akihiro

  公开号：US20090036492A1

  公开（公告）日：2009-02-05

  The present invention relates to a novel cercosporamide derivative, a pharmacologically acceptable salt thereof or an ester thereof which has an excellent hypoglycemic effect and is useful as a therapeutic and/or prophylactic agent for diabetes. A cercosporamide derivative having the general formula (I): [wherein X represents an oxygen atom or the like, R 1 represents a hydrogen atom or a C 1 -C 6 alkyl group, R 2 represents a hydrogen atom, a C 1 -C 6 alkyl group or a C 1 -C 6 halogenated alkyl group, R 3 represents a hydrogen atom or a C 1 -C 6 alkyl group, R 4 represents a C 6 -C 10 aryl group which may be substituted with one to five group(s) independently selected from Substituent Group a, or the like, n represents 1, 2 or 3, and Substituent Group a represents a halogen atom, a C 1 -C 6 alkyl group, a C 1 -C 6 halogenated alkyl group, a C 2 -C 6 alkenyl group, a C 2 -C 6 alkynyl group, a C 1 -C 6 alkoxy group, a C 1 -C 6 halogenated alkoxy group, a C 2 -C 6 alkenyloxy group, a C 2 -C 6 alkynyloxy group and the like], a pharmacologically acceptable salt thereof or an ester thereof.

  本发明涉及一种新型的环孢霉素衍生物，其具有优异的降血糖作用，可作为糖尿病治疗和/或预防制剂使用的药物学上可接受的盐或酯。 具有以下通式（I）的环孢霉素衍生物： [其中，X代表氧原子或类似物，R1代表氢原子或C1-C6烷基，R2代表氢原子、C1-C6烷基或C1-C6卤代烷基，R3代表氢原子或C1-C6烷基，R4代表C6-C10芳基，该芳基可被一个到五个独立选择的取代基a取代，n代表1、2或3，取代基a代表卤原子、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6炔基、C1-C6烷氧基、C1-C6卤代烷氧基、C2-C6烯氧基、C2-C6炔氧基等]，其药学上可接受的盐或酯。
• NOVEL CERCOSPORAMIDE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1914229B1

  公开（公告）日：2010-06-16
• Synthesis and biological evaluation of novel (−)-cercosporamide derivatives as potent selective PPARγ modulators
  作者：Akihiro Furukawa、Tsuyoshi Arita、Takehiro Fukuzaki、Makoto Mori、Takeshi Honda、Susumu Satoh、Yumi Matsui、Kenji Wakabayashi、Shinko Hayashi、Kouichi Nakamura、Kazushi Araki、Masanori Kuroha、Jun Tanaka、Satoko Wakimoto、Osamu Suzuki、Jun Ohsumi

  DOI：10.1016/j.ejmech.2012.05.040

  日期：2012.8

  Selective peroxisome proliferator-activated receptor gamma (PPAR gamma) modulators are expected to be a novel class of drugs improving plasma glucose levels without PPAR gamma-related adverse effects. As a continuation of our studies for (-)-Cercosporamide derivatives as selective PPAR gamma modulators, we synthesized substituted naphthalene type compounds and identified the most potent compound 15 (EC50 = 0.94 nM, E-max), = 38%). Compound 15 selectively activated PPAR gamma transcription and did not activate PPAR alpha and PPAR delta. The potassium salt of compound 15 showed a high solubility and a good oral bioavailability (58%). Oral administration of the potassium salt remarkably improved the plasma glucose levels of female Zucker diabetic fatty rats at 1 mg/kg. Moreover, it did not cause a plasma volume increase or a cardiac enlargement in Wistar-Imamichi rats, even at 100 mg/kg. (C) 2012 Elsevier Masson SAS. All rights reserved.